期刊
CANCER CYTOPATHOLOGY
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1002/cncy.22769
关键词
cytology smears; head and neck cancer; lung cancer; organoids; personalized and precision medicine; rare tumors; tumoroids
Patient-derived organoid models have great potential in advancing clinical cancer research, and cytology plays a vital role in organoid development. Cytologic validation ensures the use of only tumor tissue for generation, preserving its characteristics. Cytology serves as a simple and cost-effective approach in tumoroid development.
Patient-derived organoid models hold promise for advancing clinical cancer research, including diagnosis and personalized and precision medicine approaches, and cytology, in particular, plays a pivotal role in this process. These three-dimensional multicellular structures are heterogeneous, potentially maintain the cancer phenotype, and conserve the genomic, transcriptomic, and epigenomic patterns of the parental tumors. To ensure that only tumor tissue is used for organoid development, cytologic validation is necessary before initiating the process of organoid generation. Here, we explore the technology of tumor organoids and discuss the fundamental application of cytology as a simple and cost-effective approach toward organoid development. We also underscore the potential application of organoid development in drug efficacy studies for lung cancer and head and neck tumors. Additionally, we stress the importance of using fine-needle aspiration to generate tumoroids.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据